Healthcare · NSE/BSE: SUNPHARMA
Sun Pharmaceutical
Pharmaceuticals
Market Cap ₹4.31L Cr
Verdict: Exceptional
Quality Scores
Multi-Bagger
78/100
Compounder Quality
91/100
Management Credibility
90/100
Governance
85/100
Cash Flow Quality
82/100
AI Summary
Sun Pharmaceutical Industries is India's largest pharmaceutical company, evolving from a generic powerhouse to a global specialty player. The 10-year trajectory reflects a significant transformation where the company navigated intense US generic pricing pressures by pivoting toward high-margin specialty products in dermatology and ophthalmology. With a market cap of over ₹4.3 lakh crore, the company maintains a dominant 8%+ market share in India and a robust global manufacturing footprint. Financial performance has accelerated in the last 5 years, with profit growth of 17% CAGR outpacing…
Top Opportunities
- India's largest pharmaceutical company
- Shift towards high-margin Specialty pharmaceuticals (26+ products)
- Strong EBITDA margins expanding to 30%
Top Risks
- Significant spike in working capital days (185 days)
- High R&D gestation periods for specialty molecules
- US FDA regulatory scrutiny/warning letters on facilities
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.